2. Signaling Pathways
  3. Metabolic Enzyme/Protease
  4. Endogenous Metabolite
  5. Endogenous Metabolite Inhibitor

Endogenous Metabolite Inhibitor

Endogenous Metabolite Inhibitors (33):

Cat. No. Product Name Effect Purity
  • HY-B1232
    Metyrapone
    		Inhibitor 99.84%
    Metyrapone (Su-4885) is a potent and orally active 11β-hydroxylase inhibitor and an autophagy activator, also inhibits the production of aldosterone. Metyrapone inhibits synthesis of endogenous adrenal corticosteroid, decreases glucocorticoid levels, and also affects behavior and emotion. In addition, Metyrapone increases the efficiency of autophagic process via downregulation of mTOR pathway, and interacts with Pseudomonas putida cytochrome P-450. Metyrapone can be used for researching Cushing's syndrome and depression.
  • HY-106024B
    Alagebrium chloride
    		Inhibitor 99.82%
    Alagebrium chloride (ALT711) is an advanced glycation end product (AGE) inhibitor.
  • HY-B0251
    Eplerenone
    		Inhibitor 99.81%
    Eplerenone (Epoxymexrenone) is a selective, highly specific and orally active aldosterone blocker (SAB). Eplerenone also is a selective mineralocorticoid receptor antagonist (MRA) with IC50 value of 0.081 μM. Eplerenone can be used for the research of hypertension, atherosclerosis, chronic systolic heart failure (HF) and cardiovascular (CV).
  • HY-16482
    Teglicar
    		Inhibitor ≥98.0%
    Teglicar is a selective and reversible orally active liver isoform of carnitine palmitoyl-transferase 1 (L-CPT1) inhibitor with an IC50 value of 0.68 μM and a Ki value of 0.36 μM. Teglicar has a potential antihyperglycemic propert. Teglicar can be used for the research of diabetes and neurodegenerative disease including Huntington's disease (HD).
  • HY-W012977
    3,3-Dimethyl-1-butanol
    		Inhibitor 99.56%
    3,3-Dimethyl-1-butanol (DMB) is an orally active inhibitor of trimethylamine (TMA) and trimethylamine N-oxide (TMAO). 3,3-Dimethyl-1-butanol inhibits the signaling pathway of p65 NF-κB and TGF-β1/Smad3. 3,3-Dimethyl-1-butanol has potential applications in cardiovascular disease (CVD).
  • HY-150252A
    ATIC-IN-1 acetate
    		Inhibitor 99.96%
    ATIC-IN-1 (compound 14) acetate is an inhibitor targeting to Aminoimidazole carboxamide ribonucleotide transformylase/inosine monophosphate cyclohydrolase (ATIC) dimerization with a Ki value of 685 nM, whcich catalyzes de novo purine biosynthesis. ATIC dimerization is crucial for its aminoimidazole carboxamide ribonucleotide (AICAR) transformylase activity. ATIC-IN-1 acetate exhibits anti-tumor activity via reduction in cell numbers and cell division rates.
  • HY-155157
    PF-07247685
    		Inhibitor 98.66%
    PF-07247685 is a BCKDC kinase (BDK) inhibitor (EC50=2.2 nM). PF-07247685 stabilizes the interaction between BDK and BCKDH core subunit E2 and prevents phosphorylation of E1. While BDK mediates branched-chain ketoacid dehydrogenase (BCKDH) phosphorylation, and inhibition of BCKDH is involved in controlling the rate-limiting step of branched-chain amino acid (BCAA) degradation. Impaired BCAA catabolism has been associated with several diseases, particularly cardiometabolic diseases, including heart failure (HF), type 2 diabetes mellitus (T2DM), non-alcoholic fatty liver disease (NAFLD), and obesity. PF-07247685 improved cardiometabolic endpoints and improves glucose tolerance in mice.
  • HY-162350
    TDI-11055
    		Inhibitor 99.43%
    TDI-11055 is an inhibitor of the epigenetic reader protein 11-19 leukemia (ENL) YEATS, which drives the oncogenic transcriptional program of acute myeloid leukemia (AML), the hematopoietic malignancy AML.
  • HY-137243
    Adenosine 3',5'-diphosphate disodium
    		Inhibitor 99.12%
    Adenosine 3',5'-diphosphate disodium is an hydroxysteroid sulfotransferases inhibitor.
  • HY-155156
    PF-07238025
    		Inhibitor 99.46%
    PF-07238025 is a BCKDC kinase (BDK) inhibitor (EC50=19 nM). PF-07238025 stabilizes the interaction between BDK and BCKDH core subunit E2 and prevents phosphorylation of E1. While BDK mediates branched-chain ketoacid dehydrogenase (BCKDH) phosphorylation, and inhibition of BCKDH is involved in controlling the rate-limiting step of branched-chain amino acid (BCAA) degradation. Impaired BCAA catabolism has been associated with several diseases, particularly cardiometabolic diseases, including heart failure (HF), type 2 diabetes mellitus (T2DM), non-alcoholic fatty liver disease (NAFLD), and obesity. PF-07238025 improved cardiometabolic endpoints and improves glucose tolerance in mice.
  • HY-137823
    4-Nitrophenyl-N-acetyl-β-D-galactosaminide
    		Inhibitor 99.55%
    4-Nitrophenyl-N-acetyl-β-D-galactosaminide has inhibitory activity against GlcNAc and GalNAc with Kis of 1.15 mM and 0.51 mM, respectively. 4-Nitrophenyl-N-acetyl-β-D-galactosaminide is extracted from Trichomonas foetus (T. foetus)
  • HY-B0251R
    Eplerenone (Standard)
    		Inhibitor
    Eplerenone (Standard) is the analytical standard of Eplerenone. This product is intended for research and analytical applications. Eplerenone (Epoxymexrenone) is a selective, highly specific and orally active aldosterone blocker (SAB). Eplerenone also is a selective mineralocorticoid receptor antagonist (MRA) with IC50 value of 0.081 μM. Eplerenone can be used for the research of hypertension, atherosclerosis, chronic systolic heart failure (HF) and cardiovascular (CV).
  • HY-W590849
    F1874-108
    		Inhibitor 99.22%
    F1874-108 is an inhibitor of brassinosteroid biosynthesis and signal transduction.
  • HY-32004
    Coumalic acid
    		Inhibitor
    Coumalic acid is an inhibitor of human carbonic anhydrase (hCA) (KI = 0.073 μM for hCA IX; KI = 0.083 μM for hCA XII). Coumalic acid is a valuable platform compound which can be prepared from malic acid. Coumalic acid can be used in the flavorings, fragrances and cosmetics industries, as polymer components, and pharmaceutical scaffolds. Coumalic acid displays antibronchial and antimalarial activity.
  • HY-146036
    NADH-IN-1
    		Inhibitor 99.38%
    NADH-IN-1 has NADH:ubiquinone oxidoreductase inhibitory activity with an IC50 value of 27 μM. NADH-IN-1 can effectively stimulate glucose uptake in vitro. NADH-IN-1 is readily metabolised by the liver. NADH-IN-1 can be used for researching diabetes.
  • HY-B1232A
    Metyrapone Tartrate
    		Inhibitor
    Metyrapone (Su-4885) Tartrate is a potent and orally active 11β-hydroxylase inhibitor and an autophagy activator, also inhibits the production of aldosterone. Metyrapone Tartrate inhibits synthesis of endogenous adrenal corticosteroid, decreases glucocorticoid levels, and also affects behavior and emotion. In addition, Metyrapone Tartrate increases the efficiency of autophagic process via downregulation of mTOR pathway, and interacts with Pseudomonas putida cytochrome P-450. Metyrapone Tartrate can be used for researching Cushing's syndrome and depression.
  • HY-147406A
    Tonlamarsen sodium
    		Inhibitor
    Tonlamarsen sodium is a angiotensinogen synthesis reducer, with antihypertensive activity.
  • HY-172888
    SPP-037
    		Inhibitor
    SPP-037 is an orally active and selective inhibitor of ST6GAL1 (IC50: 3.59 μM). SPP-037 exhibits anti-MDA-MB-231 cell migration activity by inhibiting integrin α2,6-sialylation and integrin-FAK-paxillin pathway. SPP-037 has anti-tumor activity in MDA-MB-231 xenograft mouse model. SPP-037 can be used in breast cancer research.
  • HY-129665
    GS-389
    		Inhibitor
    GS 389 ((±)-O,O-Dimethylcoclaurine) is a tetrahydroisoquinoline. GS-389 inhibites Cyclic AMP and cyclic AMP dependent phosphodiesterases from rat atrial and ventricular tissue. GS-389 relaxes the contraction induced by phenylephrine and high K+ in rat aortic rings.
  • HY-169334
    BDK-IN-1
    		Inhibitor
    BDK-IN-1 (compound (-)-43) is a BDK inhibitor with the IC50 of 0.23 μM and the max inhibition of 90%. BDK-IN-1 decreases the level of phospho-E1 and can be used for study of cardiometabolic diseases.